• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate (CAS No. 1245465-67-1): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate (CAS No. 1245465-67-1) is a highly versatile and significant intermediate in the field of pharmaceutical synthesis. This compound, characterized by its indazole core structure, has garnered considerable attention due to its utility in the development of various bioactive molecules. The presence of both a bromo substituent and a methyl group on the indazole ring enhances its reactivity, making it a valuable building block for medicinal chemists.

The chemical structure of Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate consists of a fused heterocyclic system containing nitrogen atoms, which is typical for indazole derivatives. This structural motif is known to exhibit a wide range of biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. The carboxylate ester group at the 4-position not only provides a site for further functionalization but also contributes to the compound's solubility and stability, making it suitable for various synthetic applications.

In recent years, there has been a surge in research focusing on indazole derivatives due to their promising pharmacological profiles. Studies have demonstrated that modifications within the indazole scaffold can significantly alter the biological activity of these compounds. For instance, the introduction of halogen atoms, such as the bromo group in Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate, can enhance binding affinity to target enzymes and receptors. This has led to the discovery of several novel drug candidates that are currently undergoing preclinical evaluation.

The synthesis of Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate involves multi-step organic reactions that require precise control over reaction conditions. The bromination step is particularly critical, as it determines the regioselectivity and yield of the final product. Advanced synthetic methodologies, such as palladium-catalyzed cross-coupling reactions, have been employed to improve the efficiency and selectivity of these transformations. These techniques not only enhance the overall yield but also minimize the formation of unwanted byproducts.

The utility of Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate extends beyond its role as a simple intermediate. It serves as a precursor for more complex molecules that exhibit enhanced pharmacological activity. For example, researchers have utilized this compound to synthesize indazole-based inhibitors targeting specific kinases involved in cancer progression. Such inhibitors have shown promising results in preclinical studies, highlighting the importance of Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate in drug discovery.

Recent advancements in computational chemistry have further facilitated the design and optimization of indazole derivatives like Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate. Molecular modeling techniques allow researchers to predict the binding modes of these compounds with biological targets with high accuracy. This has enabled the rapid identification of lead compounds that can be further refined through iterative synthetic approaches. Such computational tools are indispensable in modern drug development pipelines.

The pharmaceutical industry continues to invest heavily in indazole-based therapeutics due to their broad spectrum of biological activities. Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate plays a pivotal role in this effort by providing a versatile scaffold for structural diversification. Its unique combination of functional groups makes it an ideal candidate for generating novel drug candidates with improved efficacy and reduced toxicity.

In conclusion, Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate (CAS No. 1245465-67-1) is a cornerstone intermediate in pharmaceutical synthesis. Its structural features and reactivity make it indispensable for developing bioactive molecules with potential therapeutic applications. As research in this field progresses, it is expected that new synthetic methodologies and applications will continue to emerge, further solidifying its importance in medicinal chemistry.

• 1092351-86-4(Methyl 2-methyl-2H-indazole-5-carboxylate)
• 885518-49-0(Methyl 6-bromo-1H-indazole-4-carboxylate)
• 192945-57-6(Methyl 3-bromo-1-methyl-1H-indazole-6-carboxylate)
• 1071428-43-7(Methyl 2-methyl-2H-indazole-4-carboxylate)
• 1346597-55-4(Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate)
• 1071428-42-6(Methyl 1-methyl-1H-indazole-4-carboxylate)
• 1092351-82-0(Methyl 1-methyl-1H-indazole-5-carboxylate)
• 1245465-69-3(6-Bromo-1-methyl-1H-indazole-4-carboxylic acid)
• 1071433-01-6(Methyl 2-methyl-2H-indazole-6-carboxylate)
• 1007219-73-9(Methyl 1-methyl-1H-indazole-6-carboxylate)